Immunoassay-based techniques have historically been the analytical method
of choice for drug screening in clinical research. Presumptive detection of the
analyte of interest in a biological specimen is most often reflexed to more specific,
confirmatory testing that typically uses gas or liquid chromatography (GC or LC)
coupled to tandem mass spectrometry (MS/MS). However, incorrect presumptive
immunoassay results requiring additional testing are a common issue that may have
substantial downstream consequences for laboratory operations and total costs.
To combat this problem, an analytical LC/TOF MS method, including 84 drugs and
metabolites, has been developed for drug screening, improving overall data quality.
Za odpiranje dokumenta
kliknite tukaj …